Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine

被引:9
|
作者
Giarola-Silva, Sarah [1 ]
Coelho-dos-Reis, Jordana G. A. [1 ]
Mourao, Marina Moraes [2 ]
Campi-Azevedo, Ana Carolina [1 ]
Nakagaki Silva, Erick E. [2 ]
Luiza-Silva, Maria [3 ]
Martins, Marina Angela [1 ]
de Oliveira Silveira-Cassette, Amanda Cardoso [1 ]
Batista, Mauricio Azevedo [1 ]
Peruhype-Magalhaes, Vanessa [1 ]
do Valle Antonelli, Lis Ribeiro [4 ]
Leite Ribeiro, Jose Geraldo [5 ]
Eloi-Santos, Silvana Maria [1 ,3 ]
Machado, Alexandre Vieira [6 ]
Teixeira-Carvalho, Andrea [1 ]
Martins-Filho, Olindo Assis [1 ]
Silva Araujo, Marcio Sobreira [1 ]
机构
[1] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Integrado Pesquisas Biomarcadores, Belo Horizonte, MG, Brazil
[2] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Helmintol & Malacol Med, Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil
[4] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Biol & Imunol Parasitaria, Belo Horizonte, MG, Brazil
[5] Secretaria Estadual Saude Minas Gerais, Belo Horizonte, MG, Brazil
[6] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Imunol Doencas Virais, Belo Horizonte, MG, Brazil
关键词
H1N1; vaccine; AS03; adjuvant; Immune response; Biomarker signature; PANDEMIC H1N1 INFLUENZA; ADVERSE EVENTS; AS03; ADJUVANT; B-LYMPHOCYTES; CHILDREN; CYTOKINE; AGE; IMMUNOGENICITY; INTERLEUKIN-10; SIGNATURES;
D O I
10.1016/j.antiviral.2017.05.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4(+), CDS+ T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tIr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation. Contrasting with NAV, prominent chemokine gene expression (cxcl8,cxcl9,ccl5) and a broad spectrum up-regulation of plasmatic biomarkers (CXCL8,1-6,1L-1 beta,1L-12,1-10) was evident in AV, which showed a major involvement of TNF and IL-10. Similarly, AV induced a robust IL-10-modulated proinflammatory storm, with early and persistent involvement of TNF-alpha/IL-12/IFN-gamma axis derived from NK-cells, CD4(+) and CD8(+) T-cells along with promiscuous production of IL-4/IL-5/1L-13. Conversely, NAV promotes a concise and restricted intracytoplasmic chemokine/cytokine response, essentially mediated by TNF-alpha and IL-4, with late IL-10 production by CD8(+) T-cells. Systems biology approach underscored that AV guided the formation of an imbricate network characterized by a progressive increase in the number of neighborhood connections amongst innate and adaptive immunity. In AV, the early cross-talk between innate and adaptive immunity, followed by the triad NK/CD4(+)/CD8(+) T-cells at day3, sponsored a later/robust biomarker network. These findings indicate the relevance of adjuvanted vaccination to orchestrate broad, balanced and multifactorial cellular immune events that lead ultimately to a stronger H1N1 humoral immunity. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:70 / 82
页数:13
相关论文
共 50 条
  • [41] Antibody Response After a Single Dose of an AS03-Adjuvanted Split-Virion Influenza A (H1N1) Vaccine in Heart Transplant Recipients
    Meyer, Sven
    Adam, Matti
    Schweiger, Brunhilde
    Ilchmann, Corina
    Eulenburg, Christine
    Sattinger, Edgar
    Runte, Hendrik
    Schlueter, Michael
    Deuse, Tobias
    Reichenspurner, Hermann
    Costard-Jaeckle, Angelika
    TRANSPLANTATION, 2011, 91 (09) : 1031 - 1035
  • [42] Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix®) in renal transplant recipients
    Brakemeier, Susanne
    Schweiger, Brunhilde
    Lachmann, Nils
    Glander, Petra
    Schoenemann, Constanze
    Diekmann, Fritz
    Neumayer, Hans-Hellmut
    Budde, Klemens
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (01) : 423 - 428
  • [43] ANTIBODY RESPONSE AFTER A SINGLE DOSE OF AN AS03-ADJUVANTED SPLIT-VIRION INFLUENZA A (H1N1) VACCINE IN HEART TRANSPLANT RECIPIENTS
    Meyer, S.
    Adam, M.
    Ilchmann, C.
    Eulenburg, C.
    Sattinger, E.
    Runte, H.
    Schlueter, M.
    Deuse, T.
    Reichenspurner, H.
    Costard-Jaeckle, A.
    TRANSPLANT INTERNATIONAL, 2010, 23 : 64 - 64
  • [44] Swine influenza in Norway: a distinct lineage of influenza A(H1N1)pdm09 virus
    Forberg, Hilde
    Hauge, Anna G.
    Gjerset, Britt
    Hungnes, Olav
    Kilander, Anette
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2013, 7 : 21 - 26
  • [45] Influenza A(H1N1)pdm09 and Postpandemic Influenza in Lithuania
    Ambrozaitis, Arvydas
    Radzisauskiene, Daiva
    Zagminas, Kestutis
    Kupreviciene, Nerija
    Gravenstein, Stefan
    Jancoriene, Ligita
    OPEN MEDICINE, 2016, 11 (01): : 341 - 353
  • [46] Influenza A(H1N1)pdm09 virus and asthma
    Obuchi, Masatsugu
    Adachi, Yuichi
    Takizawa, Takenori
    Sata, Tetsutaro
    FRONTIERS IN MICROBIOLOGY, 2013, 4
  • [47] Influenza A(H5N1) Immune Response among Ferrets with Influenza A(H1N1)pdm09 Immunity
    Le Sage, Valerie
    Werner, Bailee D.
    Merrbach, Grace A.
    Petnuch, Sarah E.
    O'Connell, Aoife K.
    Simmons, Holly C.
    Mccarthy, Kevin R.
    Reed, Douglas S.
    Moncla, Louise H.
    Bhavsar, Disha
    Krammer, Florian
    Crossland, Nicholas A.
    Mcelroy, Anita K.
    Duprex, W. Paul
    Lakdawala, Seema S.
    EMERGING INFECTIOUS DISEASES, 2025, 31 (03) : 477 - 487
  • [48] Safety and immunogenicity of 2010-2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine Results of a randomized trial
    Scheifele, David W.
    Dionne, Marc
    Ward, Brian J.
    Cooper, Curtis
    Vanderkooi, Otto G.
    Li, Yan
    Halperin, Scott A.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (01) : 136 - 143
  • [49] Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
    Saad, Carla G. S.
    Borba, Eduardo F.
    Aikawa, Nadia E.
    Silva, Clovis A.
    Pereira, Rosa M. R.
    Calich, Ana Luisa
    Moraes, Julio C. B.
    Ribeiro, Ana C. M.
    Viana, Vilma S. T.
    Pasoto, Sandra G.
    Carvalho, Jozelio F.
    Franca, Ivan L. A.
    Guedes, Lissiane K. N.
    Shinjo, Samuel K.
    Sampaio-Barros, Percival D.
    Caleiro, Maria T.
    Goncalves, Celio R.
    Fuller, Ricardo
    Levy-Neto, Mauricio
    Timenetsky, Maria do Carmo S.
    Precioso, Alexander R.
    Bonfa, Eloisa
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) : 1068 - 1073
  • [50] Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents
    Garcia-Sicilia, J.
    Gillard, P.
    Carmona, A.
    Tejedor, J. C.
    Aristegui, J.
    Merino, J. M.
    Behre, U.
    Caplanusi, A.
    Vaman, T.
    Dieussaert, I.
    VACCINE, 2011, 29 (26) : 4353 - 4361